Detalles de la búsqueda
1.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Ann Oncol;
2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38729566
2.
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Ann Oncol;
33(11): 1149-1158, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961599
3.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Ann Oncol;
33(4): 384-394, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35093516
4.
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Ann Oncol;
32(1): 49-57, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098995
5.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Ann Oncol;
31(9): 1216-1222, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32461104
6.
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Ann Oncol;
30(8): 1279-1288, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31095287
7.
Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases.
Arch Gynecol Obstet;
300(1): 161-168, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31011878
8.
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Ann Oncol;
29(1): 178-185, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29069370
9.
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat;
168(1): 179-187, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177689
10.
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Ann Oncol;
28(8): 1803-1810, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28459941
11.
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Ann Oncol;
33(7): 743-744, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35595658
12.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Ann Oncol;
28(8): 1700-1712, 2017 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28838210
13.
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
Br J Cancer;
114(8): 863-71, 2016 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27031854
14.
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Ann Oncol;
27(6): 1035-1040, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27022068
15.
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Ann Oncol;
26(1): 113-119, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355722
16.
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Ann Oncol;
26(1): 95-100, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355716
17.
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Ann Oncol;
25(1): 81-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24273046
18.
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Ann Oncol;
25(8): 1551-7, 2014 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24827128
19.
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto).
Ann Oncol;
25(12): 2363-2372, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25223482
20.
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Breast Cancer Res Treat;
143(1): 159-69, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24305979